Cargando…

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable plasma cell malignancy. Although Dexamethasone (Dex) is the most widely used therapeutic drug in MM treatment, patients develop Dex resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms driving Dex resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Li, Liu, Wei, Aldana-Masangkay, Grace, Pozhitkov, Alex, Pichiorri, Flavia, Chen, Yuan, Rosen, Steven T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725350/ https://www.ncbi.nlm.nih.gov/pubmed/34983615 http://dx.doi.org/10.1186/s13046-021-02226-9

Ejemplares similares

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Regulation of miR-34b/c-targeted gene expression program by SUMOylation
por: Li, Yi-Jia, et al.
Publicado: (2018)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

MicroRNAs: New Players in Multiple Myeloma
por: Pichiorri, Flavia, et al.
Publicado: (2011)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
por: Khalife, Jihane, et al.
Publicado: (2021)

Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines
por: Friday, Ellen, et al.
Publicado: (2011)

Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells
por: Deng, Mingyang, et al.
Publicado: (2022)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

The Role of HDAC6 in Cancer
por: Aldana-Masangkay, Grace I., et al.
Publicado: (2011)

Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF-1α and Oct4
por: Jiang, Zhongmin, et al.
Publicado: (2020)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
por: Mele, Giuseppe, et al.
Publicado: (2018)

Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma
por: Georgakopoulos, Constantine D., et al.
Publicado: (2019)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
por: Lewinsky, Hadas, et al.
Publicado: (2021)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
por: Chng, W-J, et al.
Publicado: (2017)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_49ff5d02ufvkrv97rfed1tria7